Xarelto Firms Settle $775 Million in Lawsuits Over Bleeding Risks

At the end of March, Bayer and Johnson & Johnson, the drug companies that make and sell Xarelto (rivaroxaban), agreed to pay $775 million to resolve more than 25,000 lawsuits alleging the drug failed to provide adequate warning. Possible bleeding risks.

Since 2011 when he was The US Food and Drug Administration (FDA) approved for the first time Using Xarelto to treat blood clots, the drug has been prescribed More than 44 million times In the United States alone. The drug is most commonly used to help prevent blood clots in patients with atrial fibrillation (AF) and for people who have had knee or hip replacement surgery.

When the lawsuits were first filed about five years ago, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) closely reviewed its label information and determined that it clearly communicated the benefits of Xarelto, according to company spokesperson Sarah Freeman.

Although both Johnson & Johnson And the bayer Refuting claims that the drug did not provide adequate notice about the potentially fatal bleeding risks, the companies decided that settling the claims would be the best course of action in terms of time, resources and ultimately patient care.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button